Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
168 hedge funds and large institutions have $2.51B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 69 increasing their positions, 47 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
50% more capital invested
Capital invested by funds: $1.68B → $2.51B (+$837M)
47% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 47
14% more funds holding
Funds holding: 148 → 168 (+20)
6% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $23.4M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.3M |
| 2 |
BlackRock
New York
|
+$51.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$34.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$19M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$46.9M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$24.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.6M |
| 4 |
Renaissance Technologies
New York
|
-$17.2M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15.2M |
DCPH Hedge Fund Activity: Q2 2020 in Review
168 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2020, worth a combined $2.51B — up 50% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new DCPH positions and 13 closed out — a net gain of 20 holders — while 69 added to existing stakes and 47 trimmed.
The largest buyer was Vanguard Group, adding an estimated $55.3M. The largest seller was New Leaf Venture Partners, cutting an estimated $46.9M.
- 168 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2020, up from 148 in Q1 2020.
- Funds reported $2.51B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 50% quarter-over-quarter.
- 33 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 13 closed out, a net change of +20 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was Vanguard Group, an estimated $55.3M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was New Leaf Venture Partners, an estimated $46.9M sold.
Based on aggregated 13F filings for Q2 2020.